Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial
James Russell Pike(Johns Hopkins University), Frank R. Lin(Johns Hopkins University), Christine Mitchell(Johns Hopkins University), Theresa H. Chisolm(University of South Florida), Nasya Tan(University of Michigan), Jennifer A. Deal(Johns Hopkins University), James S. Pankow(University of Minnesota System), Kathleen M. Hayden(Wake Forest University), Nancy W. Glynn(University of Pittsburgh), Victoria A. Sanchez(University of South Florida), Nicholas S. Reed(Beatson West of Scotland Cancer Centre), Josef Coresh(Johns Hopkins University), Alison Huang(NYU Langone Health), Michelle Arnold(University of South Florida), Adele M. Goman(Johns Hopkins University), David Couper(University of North Carolina at Chapel Hill), Kevin Sullivan(Rutgers, The State University of New Jersey)
Cited by 13
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults
|New England Journal of Medicine|2010|1.6k
Hearing Loss and Incident Dementia
|Archives of Neurology|2011|1.5k
Hearing loss and cognition in the Baltimore Longitudinal Study of Aging.
|Neuropsychology|2011|702